Black Diamond Therapeutics (BDTX)
$5.05
Live
Insights on Black Diamond Therapeutics
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 321.7%
Performance
- $4.93$5.05$5.05
2.38%
Downside
Day's Volatility :2.38%
Upside
0.0%
- $1.43$6.85$5.05
71.68%
Downside
52 Weeks Volatility :79.12%
Upside
26.28%
Returns
| Period | Black Diamond Therapeutics | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 77.54% | 1.7% | 0.0% |
6 Months | 164.92% | 11.3% | 0.0% |
1 Year | 230.72% | 5.4% | 1.3% |
3 Years | -81.85% | 13.9% | -22.1% |
Highlights
Market Capitalization | 259.1M |
Book Value | $2.26 |
Earnings Per Share (EPS) | -1.88 |
Wall Street Target Price | 12.8 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -34.33% |
Return On Equity TTM | -70.94% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -86.0M |
Diluted Eps TTM | -1.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.71 |
EPS Estimate Next Year | -1.79 |
EPS Estimate Current Quarter | -0.47 |
EPS Estimate Next Quarter | -0.52 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 153.47%
Technicals Summary
Sell
Neutral
Buy
Black Diamond Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Black Diamond Therapeutics | -2.5% | 164.92% | 230.72% | -81.85% | -87.18% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Black Diamond Therapeutics | NA | NA | NA | -1.71 | -0.71 | -0.34 | NA | 2.26 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Black Diamond Therapeutics | Buy | $259.1M | -87.18% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Bellevue Group AG
16.50%NEA Management Company, LLC
8.60%T. Rowe Price Investment Management,Inc.
7.59%RA Capital Management, LLC
6.82%Artal Group S A
3.96%Vanguard Group Inc
3.76%
Corporate Announcements
Black Diamond Therapeutics Earnings
Black Diamond Therapeutics’s price-to-earnings ratio stands at None
Read More
Company Information
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Organization | Black Diamond Therapeutics |
Employees | 54 |
CEO | Dr. Mark A. Velleca M.D., Ph.D. |
Industry | Health Technology |
